ON BOARD: DIRECTORS WITH PANACIS MEDICAL

David Booth

Mr. Booth is a former senior executive and director with Pfizer Inc. from which he retired in 1998 after 28 years. His most recent positions were as President and CEO of component companies of the Pfizer Medical Technology Group. Prior to joining the Medical Technology Division, he worked as Vice President Pharmaceuticals for Pfizer International and was a member of the Pfizer International Board. Since retiring from Pfizer, Mr. Booth has worked as a consultant in the healthcare arena and has served as a director on several Boards. He currently serves on the Board of CryoCath Technologies Inc., as well as on the Boards of three privately held companies in the healthcare field.

Dr. André de Villers

Dr. André de Villers obtained his degree in medicine from Université de Montréal in 1973, and subsequently became closely involved in the emergence of the biotechnology sector in Québec. From 1988 to 1993, he created and successfully managed several R&D venture capital companies, generating an investment totalling $250 million. In 1993, Dr. de Villers founded Theratechnologies, now a leader in the biotechnology field in Canada. From 1993 to 2002, Dr. de Villers held successively the positions of President and Director of R&D, President and General Manager, and President and CEO of Theratechnologies. During that period, Dr. de Villers has played a key role in the creation of Andromed Inc., Ecopia BioSciences and Celmed BioSciences Inc. Since May 2002, he has held the position of Vice Chairman of the Board of Theratechnologies.

In 2002, Dr. de Villers’ entrepreneurship, vision, exceptional career and outstanding contribution to the biotech sector were recognized with significant awards. He received Ernst & Young’s 2002 Québec Entrepreneur of the Year award in the biotechnology category and was named emeritus member of BioQuébec’s Excelcia Club, a distinction conferred to the pioneers who have contributed to the advancement of the biotechnology industry. Since November 1999, Dr. de Villers is also Chairman of the Biopharmaceutical Companies Committee of Canada’s Research-Based Pharmaceutical Companies (Rx&D) and a member of its board of directors. He is also member of the boards of TSO3 Inc. and H3 Pharma Inc.